Expression of 20 m homologous restriction factor of complement (HRF20) (CD59) in normal human heart was immunohistochemically examined with monoclonal antibody (MAb) 1F5. HRF20 wds dearly demonstrated on the cell surface membrane and intercalated discs of myocardial cells throughout the ventricular walls. Therefore, this factor may protect n o d cardiomyocytes h m complement deposition, which has been demonstrated on infarcted cardiomyocytes. Expression of HRF20 was also observed on endothelial cells of the endocardium and on blood vessels, including arteries, capillaries, and veins, and on the Schwann-cell sheath 1993)
Introduction
Twenty KD homologous restriction factor (HRF20) (10, 12) , which is identical to P18 (19, 20) and CD59 (2, 18) , is a membrane inhibitor of homologous complement activation and plays an important role in preventing the formation of membrane attack complexes (MAC) on autologous cell membranes (ll), together with other homologous restriction factors such as decay-accelerating factor (DAF) (6, 8) and membrane co-factor protein (MCP) (17) . HRFZO was first found on erythrocytes (10, 12, 19, 20) , and has been demonstrated immunohistochemically in various human tissues such as the epidermis of the skin (15) , cells lining the hepatic sinusoids and splenic sinuses (9) , syncytiotrophoblasts of the placenta (5) , ependymal cells of the choroid plexus (9) , peripheral nerve fibers (9) , mesangial cells of the renal glomeruli (21), vascular endothelial cells in general (9) , and epithelial cells of various organs, such as bile ducts and canaliculi of the liver (5) , glomeruli, tubules, and collecting ducts of the kidney (9, 13) , bronchi and bronchioles of the of peripheral nerve fibers. In the present study, we found that the epitopes of HRF20 were well preserved for immunohistochemistry even in acetone-fd and para&ii-embedded tissues, as well as in frozen tissues that have been conventionally used for HRF20. This method using pataffrn sections allows for easier staining and greater accuracy in histological examination. (J f i k t d e m C y t d e m 41:119-122, lung (9), exocrine ducts of the pancreas (5), and ducts (5) and acini (9) of the salivary glands. On the other hand, it has been reported that H R F Z O was immunohistochemically negative in the hepatocytes and Kupffer cells of the liver (5), alveolar and bronchiolar epithelium (5, 9) , islets of Langerhans and acinar cells of the pancreas (5, 9) , and astrocytes and oligodendrocytes of the central nervous system (5, 9) . In the present study we report the immunohistochemical localization of HRF2O on the membranes of myocardial cells of the human heart, and briefly discuss its possible role in protection against myocardial injury.
Immunohistochemical staining of HRFZO in previous reports (5, 9, 13, 15) was carried out using frozen sections, whereas in the present study acetone-fixed and paraffin-embedded tissues were used. A comparison between this method and others, including frozen sections, will also be discussed.
Materials and Methods
Preparation of Tissue Specimens. Heart tissues were obtained at autopsy within 3 hr of death from two neonates and four adults. Skeletal muscle tissues (greater psoas muscle) from three adults were also taken at autopsy within 3 hr. The causes of death in these patients were unrelated to cardiac and skeletal muscle diseases. Tissue specimens from the right and left ven-119 TADA, OKADA, OKADA, TATEYAMA, E I M O tricular walls, ventricular septum, and skeletal muscle were promptly fixed in acetone and embedded in paraffin by a technique based on the AMeX method (14) . Briefly, tissues were fixed in acetone at 4°C for 3 days, then cleared in methyl benzoate and xylene, consecutively, and embedded in paraffin. For comparative study of the effects of fixation and embedding methods on immunohistochemical staining of HRF20 in the myocardial sections, heart tissues adjacent to those taken for acetone fmtion were separated into four groups. The first group was fixed in periodate-lysine-4% paraformaldehyde (PLP) for 6 hr at 4'C and washed with increasing concentrations of sucrose (10, 15, and 20%) PBS for 48 hr at 4'C. Fixed specimens were then embedded in OCT compound (Miles; Kankakee, IL). and frozen quickly in liquid nitrogen. The second group was fixed in 4% paraformaldehyde solution in phosphate buffer (pH 7.4, 0.1 M) at 4'C for 6 hr, and the third was immersed in modified methacarn fixative (methanokin-hibisoLacetic acid, 60:3010 vlv) (7) at 4'C for 48 hr. The fourth group was put into 10% neutral buffered formalin at room temperature for 8 hr. Fixed tissues of the second and fourth groups were then dehydrated in a graded ethanol series, cleared in xylene, and embedded in paraffin. Methacarnfixed tissues (the third group) were dehydrated in a graded methanol series, cleared in xylene, and embedded in paraffin.
Antibody. Anti-HRF2O moue monoclonal antibody (MAb) IF5 (mouse IgG1) was prepared from the hybridoma clone 1F5 by a method described previously (12) . The specificity of the antibody has also been described (11) .
I m m u n o~~. Innunoreactive HRF20 was demonstrated with the avidin-biotin-peroxidase (ABC) method (4) . Biotinylated anti-mouse IgG antibody and the ABC standard kit were obtained from Vector Labs (Burlingame, CA). Frozen sections were cut to a thickness of 5 wm in a cryostat, dried in air for 30 min at room temperature, and used for i"unostaining. Paraffin sections were cut to a thickness of 3 pm and deparaffinized with xylene. After washing with PBS, the sections were treated with 0.3% (vlv) hydrogen peroxide in methanol for 30 min to inactivate endogenous peroxidase. They were then immersed in a 120 dilution of non-immune goat serum for 20 min to block nonspecific immunoglobulin binding sites. After blotting of excess serum, incubation was carried out with the anti-HRF20 mouse MAb IgGl(lF5) for 1 hr at room temperature. Control sections were treated with either non-immune mouse IgGl (Becton Dickinson Immunocytometry Systems; San Jose, CA) or antibromodeoxyuridine (BrdU) monoclonal antibody (mouse IgG1) (Becton Dickinson). Since BrdU is not contained naturally in any sites of human tissues, anti-BrdU MAb composed of mouse IgGl can be used as a negative control. The sections were rinsed and incubated sequentially with biotinylated goat anti-mouse IgG antibody for 30 min and with ABC complex for 50 min. After the sections were washed with PBS, the peroxidase reaction was carried out by incubation of the sections in 0.02% (wlv) 3,3'diaminobenzidine tetrahydmchloride (Sigma) solution containing 0.003 % (vlv) hydrogen peroxide and 10 mM sodium azide. Methyl green was used as a counterstain.
Results

Acetone3xed and Parufin-embedded Zssues
HRF20 was clearly demonstrated on the surface membranes of the cardiac muscle cells in both cross-and longitudinal sections, as well as in intercalated discs between these cells in the longitudinal section (Figures la and Ib) . Staining in the cytoplasm was negative. Positive staining was also observed on the surface membranes of the skeletal muscle cells and, to a lesser degree, on the surface of smooth muscle cells of the arteries and veins in the heart and skeletal muscle tissues. In addition, HRF20 expression was shown in the Schwann-cell sheath of peripheral nerve fibers and in endothelial cells of the capillaries, arteries, veins, and endocardia (Figure la) . Control sections treated with either non-immune mouse IgGl or anti-BrdU MAb antibody (mouse IgG1) showed no positive staining at any sites.
Comparative Study of the Eflects of Fimtion and Embedding Methods
The most sensitive staining was found in PLP-frozen tissues and acetone-paraffin tissues (Figures la and IC) . In both tissues, the surface membranes of the cardiomyocytes in the cross-sections and the intercalated discs of cardiomyocytes in the longitudinal sections clearly showed positive staining (Figures la-Id) . However, owing to the poor preservation of histological architecture in the frozen sections, immunostaining of surface membranes of cardiomyocytes in the longitudinal sections of PLP-frozen tissues was inferior to that of acetone-paraffin tissues ( Figure Id) . The surface membranes of cardiomyocytes in the cross-sections of paraformaldehyde-paraffin and methacarn-paraffin tissues showed positive but much weaker staining than those of frozen tissues and acetone-paraffin tissues (Figures le and lg) . In longitudinal sections, the best immunostaining of the surface membranes was observed in acetone-paraffin tissues ( Figure Ib) . Intercalated discs of cardiomyocytes in both paraformaldehyde-paraffin and methacarn-paraffin sections were not stained positively (FigL:e If and lh). No positive staining was observed in any sites in formalin-paraffin sections.
Discussion
HRF20 is a 20,000 MW PI-anchored membrane glycoprotein which interferes with the terminal stage of complement action and plays TADA, OKADA, OKADA, TA'TEYAMA, EIMOTO a role in protecting membranes from autologous complement attack (11) . The present study shows that HRF20 is clearly expressed on membranes of cardiac muscle cells. Immunohistological localization ofHRF20 has been demonsuated in various organs and cells, as described above (5, 9, 13, 15) . However, expression of HRF20 in the heart, as well as in the smooth and skeletal muscle, has not yet been reported. The physiological and pathological significance of the existence of HRF20 on cardiac muscle cells is not yet known, but C5b-9 complexes have been demonstrated on cardiac muscle cells in areas of infarction (16) . Although the mechanism of complement deposition on infarcted cardiomyocytes remains to be elucidated, cell damage after ischemia might result from loss of the membrane's ability to inactivate deposited complement. A similar speculation may be given as an explanation of a possible mechanism for the deposition of C5b-9 complexes in necrotic muscle fibers, which has been immunohistochemically demonstrated in various muscle diseases including muscular dystrophies (3) .
In addition to HRF20, complement activation on cell membranes is also controlled by DAF (6, 8) , which prevents association of C3b with factor B and C4b with C2 (8), as well as molecules such as membrane co-factor protein (MCP) (17) , which has co-factor activity for factor I (lJ7). Recently, the presence of DAF on the surface of myocardial cells of normal individuals and its loss in the areas of myocardial infarction were demonstrated using an immunohistochemical technique with frozen sections (22). This suggests the possibility that ischemic injury to cardiomyocytes may cause loss of HRF20 from the cell membrane in the infarcted area. Both HRF2O and DAF may contribute to the progression of myocardial infarction. It is also possible that cardiomyocytes at sites where DAF and HRF20 expression is low cannot prevent complement attack. However, to resolve this issue, further studies of hearts that have experienced ischemic injury are required.
Previous studies on the immunohistochemistry of HRF20 have been done solely using frozen sections (5, 9, 13, 15) . However, acetonefixed and paraffin-embedded tissues demonstrated almost the same degree of immunohistochemical sensitivity for detection of antigenicity of HRF20 as frozen tissues. This was much better than with paraformaldehyde-or methacarnor formalin-fixed and paraffinembedded tissues. With regard to the preservation of histological architecture and adability for the usual histological and immunohistological observations, paraffin sections were superior to frozen sections. Therefore, the method presented here may contribute to further studies on the physiological and pathological significance of HRFZO.
